Bio Solution
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Bio Solution develops and supplies cell-therapy products, treatments grown from a patient's own or a donor's cells, used to repair skin damaged by burns and to restore cartilage in joints.
Its products are supplied to hospitals and clinics in South Korea, and it also provides human tissue models used by researchers to test the safety and effectiveness of substances without using animals. Listed on KOSDAQ, Korea's tech and small-cap board, the company runs two distinct business lines: approved, commercialized cell therapies and a contract testing service built around its internationally recognized tissue models.
Summary is AI-generated and may contain errors · figures from DART filings
Its burn-treatment products are listed under South Korea's national health insurance and industrial-accident insurance schemes, which govern reimbursement and patient access in the Korean market.
Bio Solution in five facts
What does Bio Solution do?
Bio Solution develops and supplies cell-therapy products, treatments grown from a patient's own or a donor's cells, used to repair skin damaged by burns and to restore cartilage in joints.
Where is Bio Solution listed and in which sector?
Bio Solution (Korean name: 바이오솔루션) trades under KRX code 086820 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Bio Solution?
Its market capitalisation was US$115.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Bio Solution's latest annual revenue and operating profit?
For fiscal year 2025, Bio Solution reported revenue of US$11.5M, an operating loss of US$3.3M and net income of US$206.3K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 17.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Material event report (convertible bonds)
Bio Solution updated the terms of convertible bonds to raise US$29.5M, about 24.1% of its market value.
Capital raise · Aug 6 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Bio Solution reported consolidated results for FY2025: revenue of US$10.5M (+18.06% year on year), an operating loss of US$2.99M and net income of US$510K (from a loss a year earlier).
Earnings · Feb 12